Physician profile
Bachar Alkhalil
NPI 1316969595
$2,782.23
in general payments reported to CMS, 2019-2025
24 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.07 · 2021: $98.08 · 2022: $593 · 2023: $569 · 2024: $864 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983 · Education: $95.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.13 |
| Education | $95.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.94 | 2022-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $284.07 | 2020-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $222.81 | 2021-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $221.69 | 2022-2025 | Tarpeyo |
| Baxter Healthcare | $217.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.40 | 2022-2025 | Jardiance |
| Travere Therapeutics, INC. | $184.75 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $142.30 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.29 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $115.04 | 2023 | |
| Horizon Therapeutics Plc | $97.81 | 2022 | |
| Opko Pharmaceuticals, LLC | $88.78 | 2023-2024 | Rayaldee |
| Tandem Diabetes Care, INC. | $75.92 | 2022 | |
| Aurinia Pharma U.S., INC. | $65.06 | 2023-2025 | Lupkynis |
| Lilly USA, LLC | $52.64 | 2024-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $51.62 | 2025 | |
| Amgen INC. | $49.80 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.36 | 2025 | Gattex |
| Cormedix INC. | $34.51 | 2025 | Defencath |
| Ardelyx, INC. | $31.75 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $31.05 | 2025 | |
| Akebia Therapeutics INC | $28.32 | 2025 | Vafseo |
| Daiichi Sankyo INC. | $26.88 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $19.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Alkhalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.